G158E H1N1 Low Reactor In South Korea



		Home	Founder	What's New	In The News	Consulting



	H1N1 Consulting Paradigm Shift Viral Evolution Intervention Monitoring Vaccine Screening Vaccine Development Expression Profiling Drug Discovery Custom Therapies Patents	Audio:Jan21 Feb2 Feb13 Feb18 twitter Live feed of underlying pandemic map data here Commentary G158E H1N1 Low Reactor In South Korea Recombinomics Commentary 23:54 March 9, 2010 Recently released NIID sequences at GISAID include A/GYEONGGI/4478/2009, which has G158E and was collected on 9/11. When G158E was reported in sequences from Germany, the CDC and Mill Hill independently determined that the isolates were low reactors, which was linked to G158E since it was the only non-synonymous HA change. NIID also released a series of more recently collected isolates in Japan which also had G158E, which dramatically increased the number of public sequences with G158E. Included in the isolates from Japan were sequences with D225N or H274Y. These low reactors with clinically significant markers were in addition to isolates with the combination of G158E and D225G found in Italy and Russia. The jump in these low reactor markers in Asia adds to the jump reported in the United States. In the latest CDC report, the number of low reactors increased from 2 to 5. An increase in low reactors was expected, as more of the target population develops immunity against wild type H1N1. However, the low reactor, receptor binding domain, and anti-viral markers have been actively jumping from one genetic background to another via recombination, which increases the number of different combinations on different genetic backgrounds. This rapid evolution raises concerns that there will be widespread vaccine failure against isolates that have resistance to anti-virals and cause more severe and fatal infections. Media Links Recombinomics Presentations Recombinomics Publications Recombinomics Paper at Nature Precedings
u

Home | Founder | What's New | In The News | Contact Us